Literature DB >> 26025394

Cardioprotective effect of miR-214 in myocardial ischemic postconditioning by down-regulation of hypoxia inducible factor 1, alpha subunit inhibitor.

D-Y Wan1, Z Zhang1, H-H Yang2.   

Abstract

To determine the significance of miR—214 expression in ischemic post—conditioning. Sixty rats were grouped to establish animal models. Immuno— luminescence and chemical methods were used to detect oxidative stress indicators. Hemodynamics indexes were measured by carotid artery intubation, and ischemia and infarction areas by Evans blue and 2,3—5 triphenyltetrazolium chloride(TTC) staining. TargetScan was used for identification and luciferase assays for verification of target genes.miR—214 and hypoxia inducible factor 1, alpha subunit inhibitor (HIF1AN) were analyzed by real—time quantitative polymerase chain reaction. Ischemia reperfusion significantly decreased left ventricular systolic pressure, +dp/dtmax, and —dp/dtmax and increased left ventricular end—diastolic pressure; ischemic post—conditioning had contrasting effects. Compared to the sham group, the ischemic/reperfusion (IR) group showed increased creatine kinase isoenzyme (CK—MB) and malondialdehyde (MDA) in the myocardium and decreased SOD. miR—214 in the IR group was down—regulated, and HIF1AN, up—regulated. Compared with the IR group, the ischemia postconditioning (IPC) group showed decreased CK—MB and MDA in the myocardium and increased SOD. The proportion of infarction area to ischemia area in IPC group declined compared to IR group. miR—214 and HIF1AN in the IPC group showed significant up— and down—regulation, respectively. Ischemic postconditioning can improve myocardial function, reduce myocardial infarction area, and prevent the ischemia reperfusion injury. miR—214 may participate in the protective function of ischemic post—conditioning by down—regulating HIF1AN.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26025394

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  7 in total

1.  MiR-146b protects cardiomyocytes injury in myocardial ischemia/reperfusion by targeting Smad4.

Authors:  Yun-Feng Di; De-Cai Li; Yan-Qing Shen; Chun-Lei Wang; Da-Yong Zhang; An-Quan Shang; Teng Hu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  MicroRNA-214-5p protects against myocardial ischemia reperfusion injury through targeting the FAS ligand.

Authors:  Yuan Lu; Jue Xi; Yao Zhang; Chenzong Li; Wensu Chen; Xiaoqin Hu; Min Zhang; Fengyun Zhang; Hui Wei; Zhi Li; Zhirong Wang
Journal:  Arch Med Sci       Date:  2019-05-28       Impact factor: 3.318

3.  Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma.

Authors:  Yu Gong; Hongli Yang; Xin Tian
Journal:  Exp Ther Med       Date:  2017-03-24       Impact factor: 2.447

Review 4.  HIF‑1α in myocardial ischemia‑reperfusion injury (Review).

Authors:  Jie Zheng; Peier Chen; Jianfeng Zhong; Yu Cheng; Hao Chen; Yuan He; Can Chen
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

Review 5.  The Interplay of Hypoxia Signaling on Mitochondrial Dysfunction and Inflammation in Cardiovascular Diseases and Cancer: From Molecular Mechanisms to Therapeutic Approaches.

Authors:  Esmaa Bouhamida; Giampaolo Morciano; Mariasole Perrone; Asrat E Kahsay; Mario Della Sala; Mariusz R Wieckowski; Francesco Fiorica; Paolo Pinton; Carlotta Giorgi; Simone Patergnani
Journal:  Biology (Basel)       Date:  2022-02-12

6.  miR-214-3p Protects and Restores the Myocardial Tissue of Rat Myocardial Infarction Model by Targeting PTEN.

Authors:  Yuan Cheng; Qing He; Tao Jin; Na Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-18       Impact factor: 2.650

7.  Decreased expression of microRNA-214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression.

Authors:  Jing Jin; Jia Yao; Fang Yue; Zhaoying Jin; Dan Li; Shan Wang
Journal:  Exp Ther Med       Date:  2018-07-04       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.